[1] So, Alexander, and Bernard Thorens. “Uric acid transport and disease.” The Journal of Clinical Investigation Vol.
120, No. 6, 2010, p. 1791.
[2] Nakagawa, Takahiko, et al. “The conundrum of hyperuricemia, metabolic syndrome, and renal disease.” Internal
and Emergency Medicine Vol. 3, No. 4, 2008, pp. 313-18.
[3] Zhao, Jiyuan, et al. “Purine metabolites in gout and asymptomatic hyperuricemia: analysis by HPLC–electrospray
tandem mass spectrometry.” Clinical Chemistry Vol. 51, No. 9, 2005, pp. 1742-44.
[4] De Luca, G., et al. “Uric acid does not affect the prevalence and extent of coronary artery disease. Results from a
prospective study.” Nutrition, Metabolism and Cardiovascular Diseases Vol. 22, No. 5, 2012, pp. 426-33.
[5] Krishnan, Eswar, et al. “Hyperuricemia and the risk for subclinical coronary atherosclerosis-data from a prospective
observational cohort study.” Arthritis Research & Therapy Vol. 13, No. 2, 2011, p. R66.
[6] Tang, Ri-Bo, et al. “Serum uric acid and risk of left atrial thrombus in patients with nonvalvular atrial fibrillation.”
Canadian Journal of Cardiology Vol. 30, No. 11, 2014, pp. 1415-21.
[7] Kuwabara, Masanari, et al. “Asymptomatic hyperuricemia without comorbidities predicts cardiometabolic diseases.”
Hypertension 2017, p. 116.
[8] Höieggen, Aud, et al. “Serum uric acid and hemorheology in borderline hypertensives and in subjects with established
hypertension and left ventricular hypertrophy.” Blood Pressure Vol. 12, No. 2, 2003, pp. 104-10.
[9] Ding, D.D., et al. “Changes of platelet α-particle membrane protein, platelet activating factor and platelet parameters
in patients with hyperuricemia.” Zhongguo shi yan xue ye xue za zhi/Zhongguo bing li sheng li xue hui
Journal of experimental hematology/Chinese Association of Pathophysiology Vol. 20, No. 2, 2012, pp. 394-97.
[10] Watanabe, Susumu, et al. “Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity.” Hypertension
Vol. 40, No. 3, 2002, pp. 355-60.
[11] Hong, Quan, et al. “Hyperuricemia induces endothelial dysfunction via mitochondrial Na+/Ca 2+ exchangermediated
mitochondrial calcium overload.” Cell Calcium Vol. 51, No. 5, 2012, pp. 402-10.
[12] Yamada, Harumi, et al. “Mechanism of the uricosuric action of the anti-inflammatory drug E3040 used to treat
inflammatory bowel disease I: study using a rat model of hyperuricemia.” Biopharmaceutics & Drug Disposition
Vol. 20, No. 2, 1999, pp. 77-83.
Kuihua Li, et al. Int J Med Res Health Sci 2017, 6(10): 1-7
7
[13] Conger, John D., and Sandor A. Falk. “Intrarenal dynamics in the pathogenesis and prevention of acute urate
nephropathy.” Journal of Clinical Investigation vol. 59, no. 5, 1977, p. 786.
[14] Chen, Chien-Chang, Yu-Jung Hsu, and Tsung-Ming Lee. “Impact of elevated uric acid on ventricular remodeling
in infarcted rats with experimental hyperuricemia.” American Journal of Physiology-Heart and Circulatory
Physiology Vol. 301, No. 3, 2011, pp. H1107-H1117.
[15] Song, Jian, et al. “The effects of non-ionic contrast medium on the hemorheology in vitro and in vivo.” Clinical
Hemorheology and Microcirculation Vol. 58, No. 3, 2014, pp. 385-93.
[16] Mazzali, Marilda, et al. “Elevated uric acid increases blood pressure in the rat by a novel crystal-independent
mechanism.” Hypertension Vol. 38, No. 5, 2001, pp. 1101-06.
[17] Sánchez-Lozada, Laura G., et al. “Role of oxidative stress in the renal abnormalities induced by experimental
hyperuricemia.” American Journal of Physiology-Renal Physiology Vol. 295, No. 4, 2008, pp. F1134-F1141.
[18] Schwartz, Idit F., et al. “Hyperuricemia attenuates aortic nitric oxide generation, through inhibition of arginine
transport, in rats.” Journal of Vascular Research Vol. 48, No. 3, 2011, pp. 252-60.
[19] Tamariz, Leonardo J., et al. “Blood viscosity and hematocrit as risk factors for type 2 diabetes mellitus: the
atherosclerosis risk in communities (ARIC) study.” American Journal of Epidemiology Vol. 168, No. 10, 2008,
pp. 1153-60.
[20] Wen, Zongyao, et al. “Biophysical meanings of orientation and deformation of RBCs in shear flow field of low
viscosity with new Ektacytometry.” Science in China Series C: Life Sciences Vol. 41, No. 2, 1998, pp. 195-202.
Thank you for copying data from http://www.arastirmax.com